|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0015672,
umls-concept:C0025677,
umls-concept:C0030705,
umls-concept:C0034380,
umls-concept:C0282440,
umls-concept:C0332293,
umls-concept:C0439234,
umls-concept:C0439831,
umls-concept:C0681906,
umls-concept:C1096777,
umls-concept:C1274040,
umls-concept:C1872109
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-1-27
|
|
pubmed:abstractText |
The objective of this study was to assess the impact of certolizumab pegol (CZP) treatment on health-related quality of life (HRQoL), fatigue and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1478-6362
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
R170
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19909548-Activities of Daily Living,
pubmed-meshheading:19909548-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19909548-Antirheumatic Agents,
pubmed-meshheading:19909548-Arthritis, Rheumatoid,
pubmed-meshheading:19909548-Double-Blind Method,
pubmed-meshheading:19909548-Drug Therapy, Combination,
pubmed-meshheading:19909548-Fatigue,
pubmed-meshheading:19909548-Female,
pubmed-meshheading:19909548-Humans,
pubmed-meshheading:19909548-Immunoglobulin Fab Fragments,
pubmed-meshheading:19909548-Male,
pubmed-meshheading:19909548-Methotrexate,
pubmed-meshheading:19909548-Middle Aged,
pubmed-meshheading:19909548-Pain,
pubmed-meshheading:19909548-Pain Measurement,
pubmed-meshheading:19909548-Polyethylene Glycols,
pubmed-meshheading:19909548-Quality of Life,
pubmed-meshheading:19909548-Recovery of Function,
pubmed-meshheading:19909548-Severity of Illness Index
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
|
|
pubmed:affiliation |
Division of Immunology/Rheumatology, Stanford University School of Medicine, 306 Ramona Road, Palo Alto, CA, 94028, USA. vstrand@aol.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
